You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A2A receptor blockade for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARY Sepsis is a clinical syndrome that complicates severe infectionSepsis remains the leading cause of morbidity and mortality in critically ill patientsThere are no specific FDA approved medicines for the treatment of sepsisCurrent concepts of the pathophysiology of sepsis suggest that organ failure and mortality in sepsis are caused by inappropriate regulation of the immune systemThis manife ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A2B receptor stimulation for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARYSepsis is a medical condition caused by an overwhelming systemic inflammatory response to infection. Although the underlying infection can now be efficiently treated with antibiotics, there are no effective therapies to control the organ damage caused by the inflammatory response of the host. As a result, sepsis is the leading cause of mortality in intensive care units and is the tenth lead ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. AC5 Inhibitor for Obesity

    SBC: VASADE BIOSCIENCES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a drug that will be therapeutic for obesity and diabetes and improve exercise tolerance. Obesity, diabetes and exercise are inextricably linked such that an agent that improves exercise tolerance or prevents obesity or the development of diabetes will likely have a therapeutic role in all three conditions. Obesity is a gl ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Advanced Absorbance Detection for the AUC

    SBC: AVIV BIOMEDICAL INC            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this STTR is to produce a commercially available rapid-scan absorbance optical detection system for XLA/I analytical ultracentrifuges. The currently available absorbance optical system provided by the analytical ultracentrifuge manufacturer is not optimized for sedimentation velocity analysis, the most commonly used analytical ultracentrifugation ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Advanced Cannula Development for Coronary Sinus Access

    SBC: STRATEGIC PACING SYSTEMS LLC            Topic: NHLBI

    DESCRIPTION provided by applicant This Phase STTR will develop novel techniques for coronary sinus access The coronary sinus provides unique anatomic and physiologic proximity to all four cardiac chambers and the coronary circulation For example the coronary sinus is used for left ventricular lead insertion for biventricular pacing or cardiac resynchronization Mor than such implan ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Affordable, UV-, heat- and water-resistant radiochromic film composed of diacetylenes having chromophoric groups

    SBC: JP LABORATORIES INC            Topic: 300

    Project Summary: Self-developing, instant radiochromic films based on the solid-state polymerization of diacetylenes (R-C≡C-C≡C- R’, where R and R’ are substituent groups) are used for measuring radiation therapy dose. Currently available radiochromic films, e.g., the GafChromicTM EBT films from Ashland (Bridgewater, NJ, USA), have many drawbacks such as they are very expensive, sensitive ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A Hemoadsorptive Device for the Treatment of SIRS

    SBC: MEDASORB TECHNOLOGIES, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall objective of the proposed project is to develop a hemoperfusion device for the clinical treatment of sepsis and other conditions related to the Systemic Inflammatory Response Syndrome (SIRS). RenalTech International and Dr. John Kellum of the University of Pittsburgh have completed promising in vitro and in vivo laboratory studies in several mode ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  8. A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    PROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with humans results in infection. Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In the Americ ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis

    SBC: Generx+, Inc.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The investigators have developed a plasmid vector that expresses the normal human alpha-1 antitrypsin (AAT) gene in human respiratory epithelium when delivered as a plasmid-cationic liposome complex. In subjects with inherited AAT deficiency, they showed that liposome mediated transfer of the normal AAT gene to the nasal respiratory epi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  10. A MECHANICAL/NEURAL LIMB PROSTHETIC INTERFACE

    SBC: ORTHOGEN LLC            Topic: N/A

    DESCRIPTION (Provided by Applicant): Each year over 6,100 Americans undergo upper limb amputation requiring the use of prosthetic devices. With current devices, the patient is unable to mechanically and electrically control the prosthetic to mimic normal function. When nerves are severed or disrupted, the information for control is still present. A better, more natural control of the prosthesis co ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government